This work constitutes the first international scientific report on the evaluation of a flavovirus covering protein in monkeys and forsees its utility as vaccinal subunity. It is also the first study with fusion proteins using a carrier protein already validated in clinic assay, which allows it to be used in humans. This work reports protection against viremia development, what has not been fulfilled before with other immunogens. It is a part of one of the most prioritized macroprojects in our country. The development of a vaccine against dengue constitutes a great contribution since this desease is one of the major health risks for most of the world population.

This research defines new molecular entities resulting immunogenic and pathogenic in a desease to which effective vaccines are not reported yet.

These results conform a part of the national efforts to obtain a vaccine against dengue, placing Cuba among the leading contries in dengue basic and applied research . It has 4 publications and a request of patent presented in PCT, USA and several Latin American countries in 2002. Results have been presented in 6 international scientific events with 25 works presented.